Part of a Project Commissioned by the Korea Disease Control and Prevention Agency’s National Institute of Health
Supporting the Entire Non-Clinical Phase, Including Production of Trial Samples

On March 6, ST Pharm announced that it has begun production of non-clinical trial samples for its Nipah virus messenger ribonucleic acid (mRNA) vaccine.


This initiative is part of a project commissioned by the Korea Disease Control and Prevention Agency’s National Institute of Health, titled “Production of Non-Clinical Samples and Safety Evaluation of Pandemic-Response Infectious Disease Vaccine Candidates.” The goal is to advance domestically discovered infectious disease vaccine candidates to a level suitable for commercialization and to lay the groundwork for rapid entry into clinical trials in the future.

Aerial view of ST Pharm Banwol Plant. ST Pharm

Aerial view of ST Pharm Banwol Plant. ST Pharm

View original image

Nipah virus infection is a fatal zoonotic disease with the potential for human-to-human transmission. The World Health Organization (WHO) has designated it as a priority pathogen due to its significant public health risk. However, since there are currently no approved vaccines or treatments, the need for proactive research and development continues to be emphasized.


Through this assignment, ST Pharm will support the entire non-clinical phase, including vaccine manufacturing process development, establishment of analytical methods, and production of toxicology study samples. The company will utilize its proprietary platform technologies, such as “SmartCap,” which incorporates the essential 5' capping technology for mRNA vaccines, as well as “STLNP,” which features lipid nanoparticle (LNP) delivery technology, in the production of vaccine samples.



A representative from ST Pharm stated, “We plan to systematically complete the production of non-clinical trial samples for the mRNA vaccine candidate that employs ST Pharm’s platform technology as part of this project,” adding, “We will contribute to enhancing the nation’s vaccine development capabilities, enabling a swift response to potential future pandemics.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing